GB1498261A - Influenza vaccines - Google Patents

Influenza vaccines

Info

Publication number
GB1498261A
GB1498261A GB1290/75A GB129075A GB1498261A GB 1498261 A GB1498261 A GB 1498261A GB 1290/75 A GB1290/75 A GB 1290/75A GB 129075 A GB129075 A GB 129075A GB 1498261 A GB1498261 A GB 1498261A
Authority
GB
United Kingdom
Prior art keywords
influenza
components
virus
type
cationic detergent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1290/75A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of GB1498261A publication Critical patent/GB1498261A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
GB1290/75A 1974-01-14 1975-01-13 Influenza vaccines Expired GB1498261A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH44774A CH589453A5 (US20110009641A1-20110113-C00116.png) 1974-01-14 1974-01-14

Publications (1)

Publication Number Publication Date
GB1498261A true GB1498261A (en) 1978-01-18

Family

ID=4187233

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1290/75A Expired GB1498261A (en) 1974-01-14 1975-01-13 Influenza vaccines

Country Status (27)

Country Link
JP (2) JPS58407B2 (US20110009641A1-20110113-C00116.png)
AT (1) AT345449B (US20110009641A1-20110113-C00116.png)
AU (1) AU500250B2 (US20110009641A1-20110113-C00116.png)
BE (1) BE824372A (US20110009641A1-20110113-C00116.png)
CA (1) CA1049406A (US20110009641A1-20110113-C00116.png)
CH (1) CH589453A5 (US20110009641A1-20110113-C00116.png)
CS (1) CS191254B2 (US20110009641A1-20110113-C00116.png)
DD (1) DD116239A5 (US20110009641A1-20110113-C00116.png)
DE (1) DE2500785B2 (US20110009641A1-20110113-C00116.png)
DK (1) DK140003B (US20110009641A1-20110113-C00116.png)
ES (1) ES433759A1 (US20110009641A1-20110113-C00116.png)
FI (1) FI54053C (US20110009641A1-20110113-C00116.png)
FR (1) FR2257305B1 (US20110009641A1-20110113-C00116.png)
GB (1) GB1498261A (US20110009641A1-20110113-C00116.png)
HK (1) HK56380A (US20110009641A1-20110113-C00116.png)
HU (1) HU173920B (US20110009641A1-20110113-C00116.png)
IE (1) IE40794B1 (US20110009641A1-20110113-C00116.png)
IL (1) IL46426A (US20110009641A1-20110113-C00116.png)
MY (1) MY8100204A (US20110009641A1-20110113-C00116.png)
NL (1) NL166622C (US20110009641A1-20110113-C00116.png)
NO (1) NO143128C (US20110009641A1-20110113-C00116.png)
PH (1) PH14458A (US20110009641A1-20110113-C00116.png)
PL (1) PL93689B1 (US20110009641A1-20110113-C00116.png)
SE (1) SE427238B (US20110009641A1-20110113-C00116.png)
SU (1) SU616997A3 (US20110009641A1-20110113-C00116.png)
YU (1) YU41289B (US20110009641A1-20110113-C00116.png)
ZA (1) ZA75259B (US20110009641A1-20110113-C00116.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6793928B1 (en) 1997-11-25 2004-09-21 Duphar International Research Bv Vaccines with an LTB adjuvant
WO2009029695A1 (en) * 2007-08-28 2009-03-05 Baxter International Inc. Method for producing viral vaccines
WO2015071177A1 (en) 2013-11-15 2015-05-21 Novartis Ag Removal of residual cell culture impurities

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2829089A1 (de) * 1977-07-13 1979-02-01 Sandoz Ag Subunit-vakzine
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
DE19938767C2 (de) * 1999-08-16 2002-10-24 Tad Pharma Gmbh Spaltimpfstoffe
PT2301572E (pt) * 2005-11-01 2014-12-22 Novartis Vaccines & Diagnostic Vacinas virais derivadas de células com níveis baixos de adn celular residual

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6793928B1 (en) 1997-11-25 2004-09-21 Duphar International Research Bv Vaccines with an LTB adjuvant
WO2009029695A1 (en) * 2007-08-28 2009-03-05 Baxter International Inc. Method for producing viral vaccines
US8497112B2 (en) 2007-08-28 2013-07-30 Baxter International Inc. Method for producing viral vaccines
RU2496519C2 (ru) * 2007-08-28 2013-10-27 Бакстер Интернэшнл Инк. Способ получения препарата, содержащего вирусные антигены, и применение препарата
AU2008293513B2 (en) * 2007-08-28 2013-11-21 Nanotherapeutics, Inc. Method for producing viral vaccines
WO2015071177A1 (en) 2013-11-15 2015-05-21 Novartis Ag Removal of residual cell culture impurities

Also Published As

Publication number Publication date
FR2257305B1 (US20110009641A1-20110113-C00116.png) 1982-03-19
DE2500785C3 (US20110009641A1-20110113-C00116.png) 1980-09-11
NL166622C (nl) 1981-09-15
HU173920B (hu) 1979-09-28
JPS56127319A (en) 1981-10-06
IL46426A0 (en) 1975-04-25
MY8100204A (en) 1981-12-31
YU41289B (en) 1987-02-28
FR2257305A1 (US20110009641A1-20110113-C00116.png) 1975-08-08
FI750014A (US20110009641A1-20110113-C00116.png) 1975-07-15
AU7730575A (en) 1976-07-15
DK140003B (da) 1979-06-05
FI54053C (fi) 1978-10-10
NL166622B (nl) 1981-04-15
DD116239A5 (US20110009641A1-20110113-C00116.png) 1975-11-12
NL7500301A (nl) 1975-07-16
YU5875A (en) 1984-04-30
NO143128C (no) 1980-12-29
ZA75259B (en) 1976-08-25
ATA21475A (de) 1978-01-15
JPS58407B2 (ja) 1983-01-06
DK1475A (US20110009641A1-20110113-C00116.png) 1975-09-01
SU616997A3 (ru) 1978-07-25
AT345449B (de) 1978-09-11
PH14458A (en) 1981-07-29
DE2500785B2 (de) 1980-01-03
CS191254B2 (en) 1979-06-29
JPS50100224A (US20110009641A1-20110113-C00116.png) 1975-08-08
NO143128B (no) 1980-09-15
SE427238B (sv) 1983-03-21
ES433759A1 (es) 1977-02-16
CA1049406A (en) 1979-02-27
DK140003C (US20110009641A1-20110113-C00116.png) 1979-10-29
AU500250B2 (en) 1979-05-17
BE824372A (fr) 1975-07-14
SE7500130L (US20110009641A1-20110113-C00116.png) 1975-07-15
IE40794L (en) 1975-07-14
FI54053B (fi) 1978-06-30
NO750031L (US20110009641A1-20110113-C00116.png) 1975-08-11
IE40794B1 (en) 1979-08-15
JPS6035326B2 (ja) 1985-08-14
HK56380A (en) 1980-10-16
IL46426A (en) 1978-01-31
DE2500785A1 (de) 1975-07-31
PL93689B1 (US20110009641A1-20110113-C00116.png) 1977-06-30
CH589453A5 (US20110009641A1-20110113-C00116.png) 1977-07-15

Similar Documents

Publication Publication Date Title
AU2684792A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
BR9106374A (pt) Vacina oral e processo de extrair uma imunoresponsta em um mamifero
GB1498261A (en) Influenza vaccines
AU6489986A (en) Thymidine kinase deletion mutants of bovine herpersvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same
KR850001700A (ko) 단순 헤르페스 바이러스 서브유니트 왁진(Herpes Simplex Virus Subuait Vaccine)의 제조방법
US3674864A (en) Process for stabilizing preparations of interfering viruses
Kurrle et al. Influenza virus‐specific T cell‐mediated cytotoxicity: integration of the virus antigen into the target cell membrane is essential for target cell formation
Bang Filamentous forms of Newcastle virus
ES8203225A1 (es) Procedimiento para aislar antigenos glicoproteicos de un vi-rus
GB1292803A (en) Improvements relating to the production of antigens
GB2001326A (en) Glycoproteins from paramyxovirus and vaccines therefrom
ES430415A1 (es) Un procedimiento para preparar una vacuna de virus de la gripe atenuado.
Russell et al. Mumps Viral Cytolysin: I. Action on Human Epithelial Cells in Tissue Culture
GB1256457A (en) Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation
AU5573196A (en) A pluripotent vaccine against enveloped viruses
GB660109A (en) Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine
GB1140316A (en) Influenza virus sub-unit vaccine
GB928807A (en) Combined poliomyelitis-diphtheria-tetanus-pertussis antigen and methods for its manufacture
GB1016586A (en) Vaccine for immunization of dogs against distemper and hepatitis contagiosa canis
GB1214135A (en) Vaccines
Greer et al. Electron microscope study of the interaction of vaccinia virus with macrophages from immunized and nonimmunized rabbits
GB777018A (en) Poliomyelitis vaccine products and methods for preparing the same
JP2841592B2 (ja) ウイルス粒子の破砕法
PT100460A (pt) Partiiculas derivadas de virus de herpes e vacinas que as contem
GB1413401A (en) Influenza vaccine

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19940113